dr. mcdermott on single-agent pembrolizumab in advanced rcc
Published 5 years ago • 262 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
1:27
dr. mcdermott on vegf/pd-1 inhibition in rcc
-
1:24
dr. mcdermott on the use of anti–pd-1 combinations in mrcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
1:05:38
watch drs. choueiri, mcdermott, and tannir, discuss the latest in rcc: https://bit.ly/3n3x59m
-
1:56
dr. cost on pembrolizumab plus axitinib in patients with rcc
-
8:34
promising treatments in advanced rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
1:08
mcdermott: immunotherapy agents in renal cell carcinoma